Dr. Ruby Sharma, M.D
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 20
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 294
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NY license 257565 -
Internal Medicine Physician
NY license 257565 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- North Shore University Hospital Manhasset, NY
- Long Island Jewish Medical Center New Hyde PArk, NY
Medical groups
- North Shore Health System Medical Faculty Group Practice Inc (164 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 294
- Services billed
- 1,104
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 291 | 148 |
| Established patient office or other outpatient visit, 40-54 minutes | 154 | 46 |
| Established patient office or other outpatient visit, 20-29 minutes | 68 | 57 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 45 | 45 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 28 | 19 |
| New patient office or other outpatient visit, 60-74 minutes | 20 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in New Hyde PArk, NY | 534 |
| Exemestane | 94 |
| Ibrance (palbociclib) | 64 |
| Letrozole Other prescribers in New Hyde PArk, NY | 49 |
| Verzenio (abemaciclib) | 41 |
| Gabapentin Other prescribers in New Hyde PArk, NY | 31 |
| Tamoxifen Citrate Other prescribers in New Hyde PArk, NY | 25 |
| Alendronate Sodium Other prescribers in New Hyde PArk, NY | 20 |
| Kisqali (ribociclib succinate) | 16 |
| Eliquis (apixaban) Other prescribers in New Hyde PArk, NY | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 2 payments worth $198 in total to this clinician.
| Daiichi Sankyo Inc. | $198 |
|---|
| Food and Beverage | $198 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $224,659 in research payments for these studies, mostly to the institutions running them.
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT05514054 - CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase In…
AstraZeneca UK Limited - A phase iii multicenter randomized open label study comparing atezolizumab anti pd L1 antibody
Hoffmann-la Roche Limited - A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib Fulvestrant Versus Placebo Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive…
AstraZeneca UK Limited - Pallaspalbociclib collaborative adjuvant studya randomized phase iii trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hr or HER2 early breast cancer WI…
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.